1)Koruth JS, et al:The clinical use of ivabradine. J Am Coll Cardiol 70:1777-1784, 2017
2)Swedberg K, et al:Ivabradine and outcomes in chronic heart failure(SHIFT);A randomised placebo-controlled study. Lancet 376:875-885, 2010
3)Tardif JC, et al:Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function;Results from the shift echocardiography substudy. Eur Heart J 32:2507-2515, 2011
4)Tsutsui H, et al:Efficacy and safety of ivabradine in Japanese patients with chronic heart failure;J-SHIFT Study. Circ J 83:2049-2060, 2019
5)Colin P, et al:Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 284:676-682, 2003
6)Ponikowski P, et al:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure;The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)developed with the special contribution of the Heart Failure Association(HFA)of the ESC. Eur Heart J 37:2129-2200, 2016
7)Böhm M, et al:Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure;Analysis from the SHIFT study. Clin Res Cardiol 102:11-22, 2013
8)Swedberg K, et al:Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure;Is there an influence of beta-blocker dose?;Findings from the SHIFT study. J Am Coll Cardiol 59:1938-1945, 2012
9)Chiu MH, et al:Initiation of ivabradine in cardiogenic shock. ESC Heart Fail 6:1088-1091, 2019